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RESULTS CONTINUED

INTRODUCTION

RESULTS

Post-operative atrial fibrillation (POAF)
following open-heart procedures affects 3050% of patients. It’s presence has negative
prognostic indications for the patient.
Advanced age is associated with higher
incidence of POAF, making it a potentially
growing problem.

Population
242 total patients, 146 (60%) on protocol.
Median age was 68 (IQR 59-73), 73% were
male, and the majority of operations were
CABG (46%), Valve (32%), or Combined
(20%).

Complications include increased morbidity,
mortality, length of stay, and as a result
increased resource utilization.
The most effective prophylactic medication
for cardiac procedures is amiodarone, shown
to be superior for preventing and treating
atrial fibrillation.

PROBLEM STATEMENT
The aim of this investigation is to improve
the outcomes in open-heart surgery patients
by initiating amiodarone prophylaxis regimen
during the perioperative period.

Risk Factors for Atrial Fibrillation
Of the 10 risk factors observed,
hypertension, CHF, male sex, and advanced
age (>70 years) were the most common.
Incidence of Atrial Fibrillation
Overall incidence of POAF was 40%,
protocol patients had a 26% relative risk
reduction (35% vs 47%), however the
difference was statistically insignificant
(p=0.06). CABG patients had the most
significant decrease in POAF rates (22%
vs 37%, p=0.03), but all three of the
major procedures had relatively large risk
reductions. Patients with history of A-fib
and pulmonary HTN had the largest relative
risk reduction (42% and 51%, respectively).
Aﬀect of Amiodarone Protocol on POAF by Procedure Type

METHODS

60%
50%

This protocol was initiated for all patients
undergoing open-heart surgery, starting in
the operating room and continuing through
their stay at the hospital.
After getting approval from our IRB, a
database was created for a retrospective
chart review of patients 2 months prior
to, and 4 months following the protocol
initiation date.

Total OHS patients
June - November 2016

25

Excluded from study based
on patient disease

242

Total number
analyzed

146

96

Amiodarone
Protocol

Non-protocol

45 (47%)

Developed POAF

9.0 days

Average LOS

51 (37%)

Developed POAF

6.8 days

Average LOS

DISCUSSION
Thie significant results coming from this data
were that the initiaion of our amiodarone
protocol resulted in a decreased total length
of stay and decreased incidence of POAF
in CABG patients. Overall POAF rates were
improved, although this was not statistically
significant.
These resuls are an improvement for the
patient as it denotes earlier recovery and
decreased risk for iatrogenic illnesses, it also
is a large saviang for the hospital in a form
of resource and cost.

40%
30%

Our multidisciplinary team developed a
perioperative amiodarone protocol based on
published data.

267

Non-Protocol
Amiodarone

20%
10%
0%
Valve

CABG

CONCLUSION

Combined

Length of Stay
Amiodarone protocol patients had a
decreased average length of stay (LOS) of
6.8 days compared to 9.0 days, p-value
< 0.001. Protocol patients who did not
develop POAF had a significantly decreased
LOS compared to their non-protocol
counterparts (6.4 days vs 8.8, p=0.01).

The addition of our anti-arrhythmia
prophylaxis protocol to the standard of care
for all open-heart surgery patients resulted
in a decreased length of stay, relatively
decreased rate of POAF in ALL procedure
patients, and a significantly decreased POAF
rate in CABG patients.

FUTURE DIRECTIONS
•	Protocol will remain in place and
expansion into full treatment algorithm
•	Cost/benefit analysis to be performed

Univariate analysis and multivariate regressions were conducted to compare patient
demographics, POAF risk factors, presence
of POAF, length of stay, and mortality.
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